FDA Approves Vaccines for the 2011-2012 Flu Season
With flu season just around the corner, the FDA has approved the formulation for the 2011-2012 vaccine.
Earlier this week, the FDA announced that it has approved the influenza vaccine formulation for the 2011-2012 vaccine that will be used by the 6 manufacturers licensed to produce and distribute the vaccine in the United States.
The vaccine formulation protects against the 3 virus strains that surveillance indicates will be most common during the upcoming season and includes the same virus strains used for the 2010-2011 influenza season.
According to the CDC, between 5% and 20% of the US population develops influenza each year, leading to more than 200,000 hospitalizations from related complications. Influenza-related deaths vary yearly, ranging from a low of about 3,000 to a high of 49,000 people.
"Vaccines to prevent seasonal influenza have a long and successful track record of safety and effectiveness in the United States," said Karen Midthun, MD, director of FDA’s Center for Biologics Evaluation and Research, in a statement. "It is important to get vaccinated every year, even if the strains in the vaccine do not change, because the protection received the previous year will diminish over time and may be too low to provide protection into the next year."
In addition to the important role that health care providers play in recommending influenza vaccination for their patients, influenza vaccination of health care personnel is also important to protect themselves, their patients, their family, and the community from influenza. The FDA urges health care organizations to encourage their members to follow CDC's Advisory Committee on Immunization Practices (ACIP) recommendations to get vaccinated.
The brand names and manufacturers of the vaccines for the upcoming season are:
- Afluria, CSL Limited
- Fluarix, GlaxoSmithKline Biologicals
- FluLaval, ID Biomedical Corporation
- FluMist, MedImmune Vaccines Inc.
- Fluvirin, Novartis Vaccines and Diagnostics Limited
- Fluzone, Fluzone High-Dose
- Fluzone Intradermal, Sanofi Pasteur Inc.
Fluzone Intradermal, a vaccine that delivered into the skin using a very small needle, will be available for those aged 18 to 64 years.
Each year, experts from the FDA, World Health Organization, CDC, and others in the public health community study virus samples and patterns collected worldwide to identify virus strains likely to cause the most illness during the upcoming influenza season. Based on that information and the recommendations of the FDA’s Vaccines and
Related Biological Products Advisory Committee, the strains selected for the 2011-2012 influenza season are:
- A/California/7/09 (H1N1)-like virus (pandemic (H1N1) 2009 influenza virus)
- A/Perth /16/2009 (H3N2)-like virus
- B/Brisbane/60/2008-like virus
There is always a possibility of a less than optimal match between the virus strains predicted to circulate and the virus strains that end up causing the most illness. However, even if the vaccine and the circulating strains are not an exact match, the vaccine may reduce the severity of the illness or may help prevent influenza-related complications.
CDC's ACIP recommends that everyone 6 months of age and older receive an annual influenza vaccination. For more information on the ACIP recommendations, click here.
- CDC Report Notes Pharmacist's Key Role in Flu Vaccinations
- Influenza Vaccine Protects Expectant Mothers, Newborns
- Hispanic Seniors Less Likely to Get Flu Shots